N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial

Brain glutathione levels are decreased in schizophrenia, a disorder that often is chronic and refractory to treatment. N-acetyl cysteine (NAC) increases brain glutathione in rodents. This study was conducted to evaluate the safety and effectiveness of oral NAC (1 g orally twice daily [b.i.d.]) as an...

Full description

Saved in:

Bibliographic Details
Published in:	Biological psychiatry (1969) 2008-09, Vol.64 (5), p.361-368
Main Authors:	Berk, Michael, Copolov, David, Dean, Olivia, Lu, Kristy, Jeavons, Sue, Schapkaitz, Ian, Anderson-Hunt, Murray, Judd, Fiona, Katz, Fiona, Katz, Paul, Ording-Jespersen, Sean, Little, John, Conus, Philippe, Cuenod, Michel, Do, Kim Q., Bush, Ashley I.
Format:	Article
Language:	English
Subjects:	Acetylcysteine - therapeutic use Adjunct therapy Adult Analysis of Variance clinical trials Double-Blind Method Female Free Radical Scavengers - therapeutic use glutathione Humans Male Middle Aged Movement Disorders - drug therapy Movement Disorders - etiology n-acetyl cysteine Outcome Assessment, Health Care - methods Psychiatric Status Rating Scales Psychiatric/Mental Health schizophrenia Schizophrenia - complications Schizophrenia - drug therapy
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!